LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF ‐1α‐Dependent Glucose Metabolic Reprogramming
Journal of Cellular and Molecular Medicine · 2024
DOI: 10.1111/jcmm.70241 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Cellular and Molecular Medicine, 2024. Verfasst von Bingfu Fan und 6 weiteren Autor:innen. Beteiligte Einrichtung: General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospita…. Hauptthemen laut MEDLINE: Liver Neoplasms, Hypoxia-Inducible Factor 1, alpha Subunit, Carcinoma, Hepatocellular, Glucose. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Zhejiang Province, National Natural Science Foundation of China, Traditional Chinese Medicine Project of Zhejiang Province.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is a foetal malignancy with dismal overall survival. The molecular mechanism underlying the progression of HCC remain largely unknown. LYR motif containing 2 (LYRM2) has been identified as an oncogene in colorectal cancer; however, its expression, functions and molecular mechanism in the context of HCC has not been investigated. Data derived from The Cancer Gemome Atlas, along with findings from our patients' cohort, indicate that LYRM2 expression is elevated in HCC tissues and correlates with adverse clinicopathological features and prognosis in HCC patients. Subsequent research into the biological functions of LYRM2 has revealed that it promotes the proliferation, migration, invasion and epithelial‐mesenchymal transition of HCC cells, both in vitro and in vivo. Mechanistic insights have shown that LYRM2 interacts with HIF‐1α, enhancing the protein stability of HIF‐1α, which in turn increases cellular glycolysis and inhibits mitochondrial respiration. Moreover, the glucose metabolic reprogramming mediated by LYRM2 is implicated in its role in promoting HCC growth and metastasis. Collectively, this study identifies that LYRM2 as a novel oncogenic protein in HCC and elucidates its contribution to HCC progression through enhancing HIF‐1α‐dependent glucose metabolic reprogramming.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- General Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, C…
- Graduate School of Bengbu Medical College, Bengbu, China.
ORCID-Profile: Changwei Dou
Förderung
- Natural Science Foundation of Zhejiang Province
- National Natural Science Foundation of China
- Traditional Chinese Medicine Project of Zhejiang Province
- Basic Public Welfare Research Project of Zhejiang Province
- Medicine and Health Science and Technology Project of Zhejiang Province
- Zhejiang Provincial Medical and Health Science and Technology Plan
Zitieren
APA
Fan, B., Zhang, Y., Zhou, L., Xie, Z., Liu, J., Zhang, C., & Dou, C. (2024). LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF ‐1α‐Dependent Glucose Metabolic Reprogramming. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/jcmm.70241
Vancouver
Fan B, Zhang Y, Zhou L, Xie Z, Liu J, Zhang C, et al. LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF ‐1α‐Dependent Glucose Metabolic Reprogramming. Journal of Cellular and Molecular Medicine. 2024. doi:10.1111/jcmm.70241
BibTeX
@article{Fan2024,
author = {Fan, Bingfu and Zhang, Yueqin and Zhou, Lu and Xie, Zhongchun and Liu, Jie and Zhang, Chengwu and Dou, Changwei},
title = {LYRM2 Promotes the Growth and Metastasis of Hepatocellular Carcinoma via Enhancing HIF ‐1α‐Dependent Glucose Metabolic Reprogramming},
journal = {Journal of Cellular and Molecular Medicine},
year = {2024},
doi = {10.1111/jcmm.70241}
}
EUVIMED